Blake Borgeson sold $924K of Recursion Pharmaceuticals (RXRX)

Executed Feb 3, disclosed Feb 6, 3 days later, against a two-business-day limit.

Value, as filed

$924K

220,000 sh × $4.20

Executed

Feb 3

the trade date, as filed

Disclosed

Feb 6

3 days after the trade · past the deadline

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Blake Borgeson Director profile →

Blake Borgeson (Director) filed 8 Form 4 reports in the trailing twelve months (0 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Recursion Pharmaceuticals, Inc. (RXRX). The largest single filing was $961K of RXRX (220,000 sh × $4.37, as filed), executed Dec 2 2025.

The name

RXRX

Recursion Pharmaceuticals, Inc. RXRX · Healthcare · 38 filings in 24 months ticker →

Healthcare · Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating techn…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Blake Borgeson in RXRX

RXRXSALE Recursion Pharmaceuticals, Inc. $100K
30,000 sh × $3.34
Exec Sep 1
Filed Sep 2 · 6:01 PM ET RXRXSALE Recursion Pharmaceuticals, Inc. $158K
40,000 sh × $3.96
Exec Jul 7
Filed Jul 9 · 6:04 PM ET RXRXSALE Recursion Pharmaceuticals, Inc. $110K
30,000 sh × $3.68
Exec Jun 2
Filed Jun 4 · 5:30 PM ET RXRXSALE Recursion Pharmaceuticals, Inc. $106K
30,000 sh × $3.52
Exec May 5
Filed May 7 · 5:30 PM ET RXRXSALE Recursion Pharmaceuticals, Inc. $588K
170,000 sh × $3.46
Exec Mar 3
Filed Mar 4 · 5:30 PM ET RXRXSALE Recursion Pharmaceuticals, Inc. $959K
220,000 sh × $4.36
Exec Jan 6
Filed Jan 8 · 5:30 PM ET RXRXSALE Recursion Pharmaceuticals, Inc. $961K
220,000 sh × $4.37
Exec Dec 2 2025
Filed Dec 4 2025 · 5:30 PM ET